title: Percutaneous sclerotherapy of massive macrocystic lymphatic malformations of the face and neck using fibrin glue with OK-432 and bleomycin.
abstract: Picibanil (OK-432) and bleomycin have been used as alternative sclerosing agents for lymphatic malformations. This study evaluated the clinical curative effect of sclerotherapy using fibrin glue combined with OK-432 and bleomycin for the treatment of macrocystic lymphatic malformations of the face and neck. Fifteen paediatric patients (6 males; 9 females, aged 13 months to 14 years) who had received percutaneous sclerotherapy for massive macrocystic lymphatic malformations of the face and neck were retrospectively reviewed. Affected regions included the neck, parotid region and parapharynx, mouth floor, face and cheek, and orbital regions. All patients showed preoperative symptoms of space-occupying lesions between 4 cm × 5 cm and 12 cm × 16 cm in size. Fibrin glue with OK-432 and bleomycin was injected under general anaesthesia. All patients received preoperative and follow-up CT scans. Outcomes were assessed by three surgeons. All patients exhibited mid-facial swelling for 3-4 weeks after surgery, but no major complications. Follow-up periods ranged from 8 to 16 months. Eight lesions were completely involuted, five were mostly involuted, and two were partially involuted. Percutaneous sclerotherapy using fibrin glue with OK-432 and bleomycin provided a simple, safe, and reliable alternative treatment for massive macrocystic lymphatic malformations of the face and neck.
authors.affiliation: Department of Oral and Maxillofacial Surgery, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. drchen@vip.163.com
authors.forename: W-l
authors.initials: WL
authors.lastname: Chen
authors.forename: Z-q
authors.initials: ZQ
authors.lastname: Huang
authors.forename: Q
authors.initials: Q
authors.lastname: Chai
authors.forename: D-m
authors.initials: DM
authors.lastname: Zhang
authors.forename: Y-y
authors.initials: YY
authors.lastname: Wang
authors.forename: H-j
authors.initials: HJ
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Fan
mesh_terms: D000293:Adolescent; D000792:Angiography / Q000379:methods; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use; D002610:Cheek / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005145:Face; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D044148:Lymphatic Abnormalities / Q000628:therapy*; D008297:Male; D009059:Mouth Diseases / Q000628:therapy; D009060:Mouth Floor / Q000473:pathology; D009333:Neck / Q000473:pathology*; D009916:Orbital Diseases / Q000628:therapy; D010305:Parotid Diseases / Q000628:therapy; D010608:Pharyngeal Diseases / Q000628:therapy; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000379:methods*; D014014:Tissue Adhesives / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D015718:Fibrin Tissue Adhesive; D012597:Sclerosing Solutions; D014014:Tissue Adhesives; D001761:Bleomycin; D010844:Picibanil